Cilastatin-15N, d3

Cilastatin-15N, d3 is a 15N-labeled and deuterium labeled Cilastatin. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct[1][2][3].

Product Specifications

CAS Number

[2738376-83-3]

Product Name Alternative

MK0791-15N, d3

UNSPSC

12352211

Target

Antibiotic; Bacterial

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Purity

99.71

Solubility

1 M NaOH : 100mg/mL (ultrasonic; adjust pH to 12 with NaOH) |10 mM in DMSO|DMSO : 100mg/mL (ultrasonic) |H2O : 12.5mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)/C(NC([C@@H]1C(C)(C)C1)=O)=C/CCCCSC([2H])([2H])C([15NH2])([2H])C(O)=O

Molecular Formula

C16H23D3N 15NO5S

Molecular Weight

362.46

References & Citations

[4]The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterialmetallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39 (7) :1629-31.|[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Blanca Humanes, et al. Protective Effects of Cilastatin Against Vancomycin-Induced Nephrotoxicity. Biomed Res Int. 2015;2015:704382.|[3]P J Petersen, et al. In Vitro and in Vivo Activities of LJC10,627, a New Carbapenem With Stability to Dehydropeptidase I. Antimicrob Agents Chemother. 1991 Jan;35 (1) :203-7.